Akebia Therapeutics, Inc.
corporate_fare Company Profile
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for AKBA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for AKBA spans 10-Q, 8-K, PRE 14A, 10-K.
Recent high-impact activity:
- Akebia Refinances BlackRock Debt With Up to $140M Symbiotic Term Loan
- Akebia 10-Q: $36.9M Q3 Revenue, $14.4M Net Loss, and a 2027 Vafseo Revenue Warning
- Akebia Posts $36.9M in Third-Quarter Revenue
- Vadadustat Hits Non-Inferiority Endpoint in VOCAL, Backing Three-Times-Weekly Dosing
- VOICE Trial Data Show Vadadustat Cuts Hospitalizations vs ESA in Dialysis Patients
Financial Snapshot
Short Interest & Short Volume
3.01 days to coverFINRA reported short interest of 27,204,975 shares in AKBA as of the October 30, 2026 settlement, a 17.9% increase from the prior period — about 3.0 days to cover at its recent average daily volume. On November 20, 2026, 67.0% of AKBA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AKBA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.
Authorized Share Increase Approved · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →